Trials / Active Not Recruiting
Active Not RecruitingNCT07204964
A Study to Evaluate the Immune Response and Safety of an Influenza Vaccine in Adults 18 Years of Age and Above
A Phase 2a Randomized, Observer-Blind, Study to Evaluate the Immunogenicity and Safety of mRNA-Based Multivalent Seasonal Influenza Vaccine Candidates in Adults 18 Years of Age and Older
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 971 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the reactogenicity, safety and immune response of GlaxoSmithKline's (GSK) messenger RNA (mRNA)-based multivalent seasonal influenza vaccine candidates administered in healthy younger and older adults.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Flu mRNA (Formulation B1) | One dose of Flu mRNA (Formulation B1) received intramuscularly. |
| BIOLOGICAL | Flu mRNA (Formulation B3) | One dose of Flu mRNA (Formulation B3) received intramuscularly. |
| BIOLOGICAL | Flu mRNA(Formulation A) | One dose of Flu mRNA (Formulation A) received intramuscularly. |
| COMBINATION_PRODUCT | Comparator 1 | One dose of Comparator 1 received intramuscularly. |
| COMBINATION_PRODUCT | Comparator 2 | One dose of Comparator 2 received intramuscularly. |
| COMBINATION_PRODUCT | Comparator 3 | One dose of Comparator 3 received intramuscularly. |
Timeline
- Start date
- 2025-10-07
- Primary completion
- 2026-07-31
- Completion
- 2026-07-31
- First posted
- 2025-10-03
- Last updated
- 2026-03-27
Locations
17 sites across 2 countries: United States, Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07204964. Inclusion in this directory is not an endorsement.